A high-throughput protocol for mutation scanning of the BRCA1 and BRCA2 genes
- PMID: 21702907
- PMCID: PMC3146935
- DOI: 10.1186/1471-2407-11-265
A high-throughput protocol for mutation scanning of the BRCA1 and BRCA2 genes
Abstract
Background: Detection of mutations by DNA sequencing can be facilitated by scanning methods to identify amplicons which may have mutations. Current scanning methods used for the detection of germline sequence variants are laborious as they require post-PCR manipulation. High resolution melting (HRM) is a cost-effective rapid screening strategy, which readily detects heterozygous variants by melting curve analysis of PCR products. It is well suited to screening genes such as BRCA1 and BRCA2 as germline pathogenic mutations in these genes are always heterozygous.
Methods: Assays for the analysis of all coding regions and intron-exon boundaries of BRCA1 and BRCA2 were designed, and optimised. A final set of 94 assays which ran under identical amplification conditions were chosen for BRCA1 (36) and BRCA2 (58). Significant attention was placed on primer design to enable reproducible detection of mutations within the amplicon while minimising unnecessary detection of polymorphisms. Deoxyinosine residues were incorporated into primers that overlay intronic polymorphisms. Multiple 384 well plates were used to facilitate high throughput.
Results: 169 BRCA1 and 239 BRCA2 known sequence variants were used to test the amplicons. We also performed an extensive blinded validation of the protocol with 384 separate patient DNAs. All heterozygous variants were detected with the optimised assays.
Conclusions: This is the first HRM approach to screen the entire coding region of the BRCA1 and BRCA2 genes using one set of reaction conditions in a multi plate 384 well format using specifically designed primers. The parallel screening of a relatively large number of samples enables better detection of sequence variants. HRM has the advantages of decreasing the necessary sequencing by more than 90%. This markedly reduced cost of sequencing will result in BRCA1 and BRCA2 mutation testing becoming accessible to individuals who currently do not undergo mutation testing because of the significant costs involved.
Figures






Similar articles
-
High-resolution melting (HRM) assay for the detection of recurrent BRCA1/BRCA2 germline mutations in Tunisian breast/ovarian cancer families.Fam Cancer. 2014 Dec;13(4):603-9. doi: 10.1007/s10689-014-9740-5. Fam Cancer. 2014. PMID: 25069718
-
Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis.BMC Cancer. 2008 Feb 25;8:59. doi: 10.1186/1471-2407-8-59. BMC Cancer. 2008. PMID: 18298804 Free PMC article.
-
Advantages of the high resolution melting in the detection of BRCA1 or BRCA2 mutation carriers.Clin Biochem. 2009 Oct;42(15):1572-6. doi: 10.1016/j.clinbiochem.2009.07.010. Epub 2009 Jul 17. Clin Biochem. 2009. PMID: 19616529
-
Pitfalls and caveats in BRCA sequencing.Ultrastruct Pathol. 2006 May-Jun;30(3):229-35. doi: 10.1080/01913120500521281. Ultrastruct Pathol. 2006. PMID: 16825125 Review.
-
Enhanced mismatch mutation analysis: simultaneous detection of point mutations and large scale rearrangements by capillary electrophoresis, application to BRCA1 and BRCA2.Methods Mol Biol. 2010;653:147-80. doi: 10.1007/978-1-60761-759-4_9. Methods Mol Biol. 2010. PMID: 20721742 Review.
Cited by
-
Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes.J Pathol. 2012 Aug;227(4):446-55. doi: 10.1002/path.4042. Epub 2012 Jul 2. J Pathol. 2012. PMID: 22514011 Free PMC article.
-
Monoallelic characteristic-bearing heterozygous L1053X in BRCA2 gene among Sudanese women with breast cancer.BMC Med Genet. 2017 Aug 16;18(1):85. doi: 10.1186/s12881-017-0448-x. BMC Med Genet. 2017. PMID: 28814288 Free PMC article.
-
Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies.Oncotarget. 2016 Oct 11;7(41):66569-66585. doi: 10.18632/oncotarget.11892. Oncotarget. 2016. PMID: 27611953 Free PMC article.
-
Health professionals' evaluation of delivering treatment-focused genetic testing to women newly diagnosed with breast cancer.Fam Cancer. 2015 Jun;14(2):265-72. doi: 10.1007/s10689-014-9770-z. Fam Cancer. 2015. PMID: 25391616
-
High-resolution melting (HRM) assay for the detection of recurrent BRCA1/BRCA2 germline mutations in Tunisian breast/ovarian cancer families.Fam Cancer. 2014 Dec;13(4):603-9. doi: 10.1007/s10689-014-9740-5. Fam Cancer. 2014. PMID: 25069718
References
-
- Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH. A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1. Science. 1994;266:66–71. doi: 10.1126/science.7545954. - DOI - PubMed
-
- Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, Fields P, Narod S, Lenoir GM, Lynch H, Feunteun J, Devilee P, Cornelisse CJ, Menko FH, Daly PA, Ormiston W, McManus R, Pye C, Lewis CM, Cannon-Albright LA, Peto J, Ponder BAJ, Skolnick MH, Easton DF, Goldgar DE, Stratton MR. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265:2088–2090. doi: 10.1126/science.8091231. - DOI - PubMed
-
- Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–1130. doi: 10.1086/375033. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous